Samsara Inc vs GeneDx Holdings Corp — how do they compare? Samsara Inc trades at $38.84 (market cap $23.49B), while GeneDx Holdings Corp trades at $82.37 (market cap $2.44B). The key difference: Samsara Inc is far larger — about 9.6× GeneDx Holdings Corp's market cap, and Samsara Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| IOT | WGS | |
|---|---|---|
Market Cap | $23.49B | $2.44B |
Sector | Technology | Technology |
52-Week High | $45.22 | $167.51 |
52-Week Low | $24.25 | $34.51 |
Enterprise Value | $22.76B | $2.48B |
Signals from Pluang's Aura AI — not financial advice
Samsara (IOT) trades at $38.77, down 2.73% on the day, with a bullish technical signal from moving averages despite overbought RSI readings. Recent earnings beats and strong analyst consensus (77.8% buy ratings) support optimism, while the company projects revenue growth to $1.7B in 2026 with a return to profitability. The stock's high P/E of 403.2 reflects growth expectations amid expanding AI adoption in its connected operations platform.
Outlook remains positive with a consensus price target of $44.50, offering 14.8% upside, driven by execution on large customer growth and margin expansion. Key risks include high valuation sensitivity to earnings misses, competitive pressures in software, and macroeconomic impacts on operational spending. Institutional accumulation, such as Arrowstreet Capital's 77.1% stake increase in Q1 2026, underscores confidence.
No Aura AI signal available yet.
Trailing returns across standard periods
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →